Firebrick Pharma restarts Phase 3 trial of Nasodine nasal spray for the common cold

Firebrick Pharma announced that it is re-starting a Phase 3 clinical trial of Nasodine povidone-iodine nasal spray as the 2023 common cold season begins in the Southern Hemisphere. According to the company, the trial, which is taking place in Australia and South Africa, was paused for the summer after having fulfilled half of its recruitment goal during the 2022 cold season. The company said that the trial needs to enroll an additional 96 adults with confirmed colds.

Firebrick Executive Chairman Peter Molloy said, “Nasodine works by killing viruses, so establishing its performance in people with actual viral infections is a pivotal proof of efficacy. Typically, the common cold season starts in autumn, so we expect to see recruitment escalate over the next several months and continue through the winter, with trial completion expected in July.”

Earlier this year, Firebrick announced that it had filed a Pediatric Investigation Plan (PIP) with the EMA’s Pediatric committee for Nasodine and said that it planned to submit a marketing application for the nasal spray by the end of 2023.

Read the Firebrick Pharma press release.